FDA approves new Roche test to evaluate response to hepatitis C therapy
6 March 2013 | By Roche
Viral load test uses a novel dual-probe approach designed to manage patients being treated with antiviral therapies...
List view / Grid view
News
Gilead announces full 24-week Phase 2 results for once-daily single tablet HIV regimen containing novel prodrug TAF
5 March 2013 | By Gilead Sciences
TAF-based regimen now in Phase 3 development...
In Nigeria, a new project prompts easier insulin access
5 March 2013 | By Novo Nordisk
Novo Nordisk launches a new project to enhance the quality and accessibility of diabetes treatment in Nigeria...
Roche Chairman Franz B. Humer announces that he will not stand for re-election in 2014
5 March 2013 | By Roche
Roche to inform about plans for succession in autumn 2013...
Roche obtains EU approval for PERJETA
5 March 2013 | By Roche
Roche announced that the EMA has approved PERJETA (pertuzumab) for patients with previously untreated HER2-positive metastatic breast cancer (mBC)...
Pfizer presents Phase 3 safety and immunogenicity data on Prevnar 13® in adults with HIV
4 March 2013 | By Pfizer
Pfizer presented the results from a Phase 3 study...
Boehringer Ingelheim announces interim results from a Phase III trial in HIV patients co-infected with chronic hepatitis C
4 March 2013 | By Boehringer Ingelheim
Interim study results from STARTversoTM 4...
FDA accepts Biogen Idec’s Biologics License Application for first long-lasting factor IX therapy for hemophilia B
4 March 2013 | By Biogen Idec
“We are encouraged by the FDA’s acceptance of our application..."
Daiichi Sankyo announces organizational restructuring as of April 1, 2013
4 March 2013 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the following organizational changes taking place from April 1, 2013...
Baby born with AIDS virus appears to have been cured
3 March 2013 | By University of Mississippi
A baby born with the virus that causes AIDS appears to have been cured, scientists announced Sunday...
Sanofi and Regeneron report positive proof-of-concept data for Dupilumab
2 March 2013 | By Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting…
Novartis receives EU approval for Ilaris®
1 March 2013 | By Novartis
Novartis announced that the European Commission has approved llaris (canakinumab, ACZ885)...
PerkinElmer hosts Revolutionaries for Global Health Summit in Brussels
1 March 2013 | By Edelman (On behalf of PerkinElmer)
Revolutionaries for Global Health Summit, 5 -6 March 2013, Brussels...
Bruce Kuhlik and Merck Honored by PBI for commitment to pro bono
28 February 2013 | By Merck
Merck announces that the Pro Bono Institute (PBI) has selected Executive Vice President Bruce Kuhlik as the winner...
ViiV Healthcare announces a voluntary licence agreement with the Medicines Patent Pool to increase access to HIV medicines for children
28 February 2013 | By
Agreement brings the number of voluntary...
